CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kytopen, a transformative biotechnology company offering non-viral delivery that links the discovery, development and manufacturing of engineered cell therapies, today announced Greg Crescenzi has joined the company as Chief Commercial Officer. Crescenzi brings his extensive life sciences experience to the role and will lead Kytopen’s commercial strategy to accelerate partnerships and market expansion. The company’s platform speeds advanced therapies by enabling cell engineering without compromising functionality or viability.
“I am so grateful and honored to work with the team at Kytopen on a disruptive technology that was discovered and spun out of MIT,” said Crescenzi. “We have the opportunity to build something with significant impact on cell and gene therapy, which will enable next-generation curative cellular treatment. For most of my career, I have helped companies develop and manufacture drugs to maintain, extend or treat disease, but at Kytopen we can accelerate cures and provide access to patients suffering from devastating diseases.”
Crescenzi brings 30 years of life science leadership experience, researching, developing, marketing, or selling integral tools and technologies that helped advanced the biotechnology industry. He joins Kytopen from Cytiva (formerly GE Healthcare Life Sciences) where he served as the Enterprise Delivery Leader. While at Cytiva, Crescenzi helped build Enterprise Solutions for its Cell & Gene Therapy business including delivery of the industry’s first and subsequent CAR-T FlexFactory®, end-to-end flexible manufacturing platforms for biomanufacturing. He oversaw GE’s commercialization of their first set of Xcellerex products, stirred-tank bioreactors and mixers. Prior to joining GE Healthcare, Crescenzi held leadership positions at BD Biosciences during the commercialization of the BD Mosaic hMSC cell culture environment. He also worked on the marketing team at Pall Life Sciences, and held various business development, marketing, and R&D roles at Millipore Corporation. He holds a Bachelor of Science in Chemical Engineering from Tufts University and an MBA from Boston University.
“Greg’s results-driven strategy will help accelerate progress and build critical clinical partnerships for Kytopen,” said Paulo Garcia, Chief Executive Officer and Co-Founder of Kytopen. “We are thrilled to have his leadership experience as an integral member of our management team. His extensive work in drug discovery and manufacturing will help us further shape and execute our commercial strategy to increase access for patients. His contributions will be instrumental as we convert our current feasibility studies in beta-testing into long-term commercial collaborations.”
ABOUT KYTOPEN
Kytopen, an MIT spin-out company, has recently made its Flowfect® Tx system available to select bio-pharma partners and collaborators to accelerate their engineered cell therapy production. Kytopen’s proprietary Flowfect® technology is a flexible, complete platform solution for non-viral cell engineering that integrates the discovery, development, and manufacturing of cell and gene therapeutics. The platform speeds therapies from the bench to clinical use by enabling cell engineering without compromising functionality or viability. The Flowfect® Tx system features an automated, single use closed system that reduces risk and provides maximum control and flexibility to drive higher yields, faster approvals, and better outcomes from potentially curative cell-based treatments. For more information, visit: www.kytopen.com